Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 6

Knowledge and attitude of physicians in a major teaching hospital towards atherosclerotic risk reduction therapy in patients with peripheral arterial disease

Authors Mohammed Al-Omran

Published 15 January 2008 Volume 2007:3(6) Pages 1019—1027

Mohammed Al-Omran

Department of Surgery, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia

Background: Peripheral arterial disease (PAD) is a marker of advanced atherosclerosis with an elevated risk of cardiovascular mortality and morbidity. Although intensive risk reduction therapy is critical in reducing the adverse cardiovascular outcomes in patients with PAD, the awareness of this information among all physicians is felt to be low. Given the role of family physicians (FP), general internists (GI), cardiologists (C), and vascular surgeons (VS) in treating patients with PAD, we sought to determine their perceptions and knowledge of risk reduction therapy in these patients.

Methods and results: We conducted a cross-sectional self-administered survey of 84 physicians who work at a major teaching hospital. FP, GI, C, and VS represent 39%, 33%, 16%, and 12% of the surveyed physicians, respectively. The recommended targets of LDL-cholesterol, blood glucose and blood pressure in PAD patients were known to 37.3%, 94.1% and 35.3% of physicians, respectively. The majority of physicians reported to screen for risk factors in PAD. Although 86.3% of physicians would recommend antiplatelets therapy in PAD, only 17.6% would recommend angiotensin converting enzyme (ACE) inhibitors; 25.5% would recommend nicotine replacement therapy for smokers and 62.7% would recommend statins. Compared to other specialties, cardiologists had the lowest threshold, whereas GI had the highest threshold for initiating antiplatelets and statins for patients with PAD.

Conclusion: The perceptions towards risk reduction in PAD identify glaring knowledge and action gaps. Effective strategies to encourage health professionals to use risk reduction therapy are needed.
Keywords: peripheral arterial disease, risk reduction, atherosclerosis

Download Article [PDF] 

Readers of this article also read:

Peyton’s four-step approach: differential effects of single instructional steps on procedural and memory performance – a clarification study

Krautter M, Dittrich R, Safi A, Krautter J, Maatouk I, Moeltner A, Herzog W, Nikendei C

Advances in Medical Education and Practice 2015, 6:399-406

Published Date: 27 May 2015

Cognitive impairment after cerebrovascular stroke: Relationship to vascular risk factors

Eman M Khedr, Sherifa A Hamed, Hala K El-Shereef, Ola A Shawky, Khalid A Mohamed, et al

Neuropsychiatric Disease and Treatment 2009, 5:103-116

Published Date: 15 February 2009

Japanese study to organize proper lifestyle modifications for metabolic syndrome (J-STOP-MetS): Design and method

Masanori Munakata, Hiroki Honma, Mitugu Akasi, Takaharu Araki, Takahiko Kawamura, et al

Vascular Health and Risk Management 2008, 4:415-420

Published Date: 11 April 2008

Clinical efficacy and safety of statins in managing cardiovascular risk

Navin K Kapur, Kiran Musunuru

Vascular Health and Risk Management 2008, 4:341-353

Published Date: 11 April 2008

Adult nontwin sib concordance rates for type 2 diabetes, hypertension and metabolic syndrome among Asian Indians: The Indian Atherosclerosis Research Study

Jayashree Shanker, Saikat Kanjilal, Veena S Rao, Ganapathy Perumal, Natesha B Khadrinarasimhiah, et al

Vascular Health and Risk Management 2007, 3:1063-1068

Published Date: 15 January 2008

The applicability of home blood pressure measurement in clinical practice: A review of literature

Willem J Verberk, Abraham A Kroon, Heidi A Jongen-Vancraybex, Peter W de Leeuw

Vascular Health and Risk Management 2007, 3:959-966

Published Date: 15 January 2008

Reduction of C-reactive protein and the use of anti-hypertensives

Carmine Savoia, Ernesto L Schiffrin

Vascular Health and Risk Management 2007, 3:975-983

Published Date: 15 January 2008

Rheumatic heart disease: 15 years of clinical and immunological follow-up

Roney O Sampaio, Kellen C Fae, Lea MF Demarchi, Pablo MA Pomerantzeff, Vera D Aiello, et al

Vascular Health and Risk Management 2007, 3:1007-1017

Published Date: 15 January 2008

Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis

Peter J Little, Mandy L. Ballinger, Narin Osman

Vascular Health and Risk Management 2007, 3:117-124

Published Date: 15 March 2007

Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI)

Huyen Tran, Shamir R Mehta, John W Eikelboom

Vascular Health and Risk Management 2006, 2:379-387

Published Date: 15 December 2006